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Background: Mucoepidermoid carcinoma (MEC) of the lung is a rare malignant neoplasm. We aimed to investigate
clinicopathological features, therapies, and prognoses of eight MEC cases.
Methods: Eight patients underwent surgical treatment for pulmonary MEC between 2005 and 2012 at the Thoracic
Surgical Department of West China Hospital, Sichuan, China. The clinical data, radiological manifestation, treatment
strategy, pathological findings, and prognoses of all patients were analyzed retrospectively.
Results: Among the eight cases (four males and four females), the age of patients ranged from 35 to 71 years
(mean age 50.67 years). Two tumors were located in the upper lobes and three masses were located in the lower
lobes. The other three lumps were located in the left main bronchus, middle segmental bronchus of the right lobe,
and trachea, respectively. The characteristics of the tumors were consistent with low grade MEC (n = 6) and high
grade MEC (n = 2). All of the patients were sent for oncological evaluations, and three patients with N1 or N2
disease received chemotherapy. One of the patients died from brain metastasis at 15 months. Seven of the eight
patients were alive at the time of evaluation. The median survival time was 40 (range 8 to 88) months.
Conclusion: Mucoepidermoid tumors have to be treated by radical surgery with lymph node sampling and
dissection. Patients with low grade tumors can be expected to be cured following complete resection. Careful
histological typing plays a key role in prediction of late results, and further studies are needed.
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Mucoepidermoid carcinoma (MEC) of the lung is a
tumor of low malignant potential of bronchial gland ori-
gin, which is characterized by the presence of squamoid
cells, mucin-secreting cells, and cells of intermediate
type [1]. MEC and adenoid cystic carcinoma are both
considered to be salivary gland-type neoplasms. It usu-
ally arises in the parotid and submandibular salivary
glands and in the minor salivary glands of the oral cavity
and perimaxillary region. However, MEC is not common
in the lungs, particularly in children, accounting for only
0.1% to 0.2% of primary lung cancers [2-5]. This study
evaluated the results of eight cases that underwent sur-
gery for MEC.* Correspondence: cheguowei_hx@aliyun.com
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Patients and clinical data
Between 2005 and 2012, eight patients were operated on
for pulmonary mucoepidermoid tumors at the Thoracic
Surgical Department of West China Hospital, Sichuan,
China. These tumors accounted for 0.11% of all resected
pulmonary neoplasms in that period. The patients were
evaluated in terms of their age, gender, symptoms, diag-
nostic approaches, surgical methods, and follow-up find-
ings. Symptoms such as hemoptysis, cough, dyspnea, and
chest pain were dominated in seven patients and only one
patient was free of symptoms, detected accidentally.
All of the patients underwent routine laboratory stud-
ies, respiratory function tests, electrocardiography, chest
X-ray, computed tomography (CT) of the thorax, brain
CT or magnetic resonance imaging (MRI), and abdom-
inal CT. Fiberbronchoscopy was undertaken in six cases.
In the preoperative period, three patients had a diagnosis
of MEC, whereas the other five patients were diagnosedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mass resection with lobectomy or bronchial sleeve
resection was undertaken in all patients by a standard
posterolateral thoracotomy incision or by video-assisted
thoracoscopic surgery (VATS). All of the tumors were
staged postoperatively according to the seventh inter-
national TNM staging system. The diagnosis was verified
immunohistochemically.
All patients underwent clinical and radiological follow-
up for a median of 40 (range 8 to 88) months. All pa-
tients were assessed quarterly for the first 2 years with a
history, physical examination, and chest X-ray. Labora-
tory tests and advanced radiological methods were
requested if there were any symptoms. Additionally, all
patients or the families were asked by telephone when
the study was performed and asked about any signs of
recurrence or complications.
Statistical analysis
The statistical analysis was performed using IBM SPSS
Statistics, version 16.0 (IBM Corporation, Armonk, NY,
USA). Descriptive analyses and Kaplan −Meier survival
analysis were used.
Results
There were four male and four female patients, whose
mean age was 50.67 years (35 to 71 years). All four male
patients were heavy smokers (mean 43 packs/year (me-
dian 45, range 20 to 60)). The most common presenting
symptoms were hemoptysis and cough (Table 1). Two
tumors were located in the upper lobes and three masses
were located in the lower lobes. In three cases, the
tumor could be seen as hilar mass and there was only
one patient with partial atelectasis (Figure 1A,B,C,D). In
the other patients, peripheral nodule (n = 2) and infil-








1 49 F - Hemoptysis Yes
2 52 F - Cough, dyspnea Yes
3 71 M 60 Hemoptysis,
chest pain
No
4 69 F - Hemoptysis No
5 35 M 20 Hemoptysis,
chest pain
Yes
6 37 F - Cough Yes
7 47 M 50 - Yes
8 48 M 40 Cough, dyspnea Yes
CT, computed tomography; MEC, mucoepidermoid carcinoma; NSCLC, non-small-cesixth was located in the trachea and the eighth was
located in the middle segmental bronchus of the right
lobe, which were observed by the fiberbronchoscopy.
Three patients who had a preoperative diagnosis of
MEC had an endobronchial component and in the other
patients (n = 3) the neoplasms were not visible on bron-
choscopy. Two patients refused to have the endoscopy
for the pain caused by the examination.
Altogether, the preoperative microscopical diagnosis
was exact in three cases, but in the others (n = 5)
NSCLC was diagnosed. No mortality occurred in the
early postoperative period. The operations were per-
formed with lobectomy by standard posterolateral thora-
cotomy in two patients or by VATS in four patients; one
with main bronchial sleeve resection and the other one
with trachea sleeve resection (Table 2).
Pathological confirmation was based on routine light
microscopic sections stained by hematoxylin and eosin
(HE) (Figure 2). Histology was controlled carefully retro-
spectively in every case. The characteristics of the tu-
mors were consistent with low grade MEC (n = 6) and
high grade MEC (n = 2). All of the patients were sent for
oncological evaluations, and three patients with N1 or
N2 disease received chemotherapy. One of the patients
died from brain metastasis at 15 months. Seven of the
eight patients were alive at the time of evaluation. The
median survival time was 40 (range 8 to 88) months.
Discussion
MEC is the most common salivary gland malignancy [6].
Approximately half of tumors occur in the minor sa-
livary gland, particularly in the palate. As a malignant
tumor of bronchial gland origin, which was first de-
scribed by Smetana in 1952 [7], it has a presumed inci-
dence of 0.1% to 0.2% of all lung cancers [8]. They can




Right upper lobe 2.5/3.5 NSCLC
Left main bronchus 1/1.5 MEC
Left lower lobe 4.0/5.5 NSCLC
Right lower lobe 3.6/4 NSCLC
Left upper lobe 1.5/2 NSCLC
Trachea 1/1.5 MEC
Right lower lobe 3.2/4 NSCLC




Figure 1 Computed tomography (CT) features. (A) CT showed a mass in the middle segmental bronchus of the right lobe (arrowhead). (B)
Patient with partial atelectasis of the right lower lobe was observed. (C and D) CT revealed a mass shadow in the hilus of the right lung of the
same patient (arrowhead). CT, computed tomography.
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The mean age in our series, 50.67 years, is considerably
older than in most series. Although some studies have
reported a male predominance, most reports, including
our own, fail to demonstrate a clear predilection based
on gender. Smoking is not a major risk factor. In our
group, four patients were males and the others were









1 T2aN2M0 IIIA T2aN2M0 IIIA
2 T3N1M0 IIIA T3N0M0 IIB
3 T2aN1M0 IIA T3N1M0 IIIA
4 T2aN0M0 IB T2aN0M0 IB
5 T1aN0M0 IA T1aN0M0 IA
6 T4N1M0 IIIA T4N0M0 IIIA
7 T2aN0M0 IB T2aN0M0 IB
8 T3N0M0 IIB T3N1M0 IIIA
MEC, mucoepidermoid carcinoma; TNM, TNM classification of malignant tumors; VAprevalence with smoking or not. Symptoms are primarily
those of bronchial irritation and obstruction, and include
cough, wheezing, hemoptysis, and postobstructive pneu-
monia. Sometimes MEC can mimic that of bronchial
asthma [9]. The more worrisome constitutional symp-
toms of pain, weight loss, and malaise, which were com-
mon in the series of Turnbull and colleagues [10], reflect






MEC (low grade) Right upper lobectomy 84 Alive
MEC (low grade) Left main bronchial
sleeve resection
88 Alive
MEC (high grade) Left lower lobectomy 15 Death
MEC (low grade) Right lower lobectomy
by VATS
44 Alive
MEC (low grade) Left upper lobectomy
by VATS
48 Alive
MEC (low grade) Trachea sleeve
resection
36 Alive
MEC (low grade) Right lower lobectomy
by VATS
24 Alive




TS, video-assisted thoracoscopic surgery.
Figure 2 Histological features. (A and B) HE staining revealed MEC of the pulmonary neoplasms. (HE × 200). (C and D) HE staining revealed
MEC of the pulmonary neoplasms. (HE × 400). HE, hematoxylin and eosin; MEC, mucoepidermoid carcinoma.
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others had cough, chest pain, and dyspnea, as expected.
The majority of MECs arise from bronchial glands in
the lumen of a main, lobar, or segmental bronchus, and
CT findings are similar to those of bronchial carcinoid
tumors. According to Zwiebel et al. [11], bronchial car-
cinoid is also associated with frequent postobstructive
pneumonia or atelectasis, and the shape of the tumor is
frequently nonspherical, with its long axis parallel to that
of the nearest major bronchovascular bundle. It was dif-
ficult to predict the exact endobronchial location of the
tumors on chest radiographs, especially when they were
present at the level of the segmental bronchus. When
the tumor manifested as a solitary pulmonary nodule
without any other associated findings, the radiographic
finding was nonspecific and was not different from that
of other benign and malignant nodules. From the CT,
however, there were several clues that helped us to
determine the endobronchial location of the tumors. As
Elnayal et al. reported [12], higher FDG uptake is associ-
ated with nodal disease in patients with primary salivary
gland-type tumors of the lung but is not predictive of
survival, whereas CT features suggestive of advanced
disease correlate with worse outcome. With all tumors
being nonspherical, the direction of the longest diameter
of the tumor was parallel to the direction of the branch-
ing pattern in the corresponding airways containing the
tumor. Associated findings of distal bronchial dilatationwith mucoid impaction, postobstructive pneumonia, sub-
segmental atelectasis, or air trapping were suggestive of an
endobronchial mass. Additional ancillary findings that
indicated the endobronchial location of the tumors were
areas of peripheral lucency or a crescent of air around the
tumor. The findings were suggestive of a residual lumen
of an ectatic bronchus that was occupied by the endo-
bronchial tumor. In our cases, two tumors were located in
the upper lobes and three masses were located in the
lower lobes. Two neoplasms were observed in the left
main bronchus or middle segmental bronchus of the right
lobe, respectively, and one mass was found in the trachea
by fiberbronchoscopy. One patient showed partial atelec-
tasis of the right lower lobe.
Foci of calcification or ossification have been reported
to be present within the tumor [13]. The incidence of
calcification in MEC of the lung was much higher than
that of the more common forms of the pulmonary car-
cinomas. In our series, punctuate calcification within the
tumor was not seen in the patients. According to the re-
port by Kim et al. [14], the tumor is known to be vascu-
lar, and marked enhancement of the tumor has been
noted at CT; whereas MEC showed only mild and non-
uniform enhancement in our cases.
MEC originates from glandular tissue identical with
salivary glands located in the submucosa of the trachea
and bronchus. It is included among carcinomas of saliv-
ary gland-types along with adenoid cystic carcinoma
Shen and Che World Journal of Surgical Oncology 2014, 12:33 Page 5 of 6
http://www.wjso.com/content/12/1/33according to the WHO histological classification of lung
cancer [15]. It is characterized by a mixture of mucus-
producing, glandular and squamous epithelial cells, as
well as intermediate cells with both properties at various
percentages, and by various growth patterns such as
cystic, papillary, and solid structures. Mucus-producing
cells form lumens in some cases. They are classified as
high grade or low grade mucoepidermoids on the basis
of their histologic appearance. Low grade malignant
tumors have mostly cystic components. Microscopic in-
vasion into pulmonary parenchyma is unusual. Mild cy-
tologic atypia can be seen. Metastasis to regional lymph
nodes is distinctly unusual. High grade tumors more
commonly show areas of solid growth. Atypia, mitotic
activity, and necrosis are characteristic and regional
lymph node involvement is more frequent in these
tumors. This high grade variant can occasionally be
difficult to distinguish from adenosquamous carcinoma
[16]. Klacsmann et al. [17] proposed several criteria by
which this differentiation can be made. In mucoepider-
moid tumors the surface epithelium does not show
carcinoma in situ, and although squamous metaplasia
may be present, one would not expect to find atypical
metaplasia, except on a coincidental basis. The cells of
both solid and glandular areas of the tumor often have a
more uniform, almost bland appearance, which differs
from that usually seen in bronchogenic carcinoma in
which the malignant nuclear features and cytoplasmic
variability are usually more pronounced. Large areas of
frank keratinization, including abundant individual cell
keratinization, is a feature of bronchogenic carcinoma
that is not seen in the mucoepidermoid tumor of the
lung. In our series, the characteristics of the tumors
were consistent with low grade MEC (n = 6) and high
grade MEC (n = 2). Tumor cells had a scattering of
mucus-producing epithelial components in papillary
growth of stratified squamous epithelia with anisokaryo-
sis and minimal pleomorphism, indicating a diagnosis of
MEC.
Radical surgery based on lung cancer treatment is per-
formed for MEC, and in recent years this operation has
been frequently performed using VATS [18]. MECs of
the lung are often treated by lobectomy, sleeve resection,
local resection, segmental resection, or even endoscopic
removal. In our cases, two patients had the operations of
lobectomy by a standard posterolateral thoracotomy and
tumors in the other four patients were completely
resected by VATS; one with left main bronchial sleeve
resection and the other one with trachea sleeve resection.
Most patients with this disease have a favorable outcome
after a complete resection [19]. However, the disease may
recur in distant organs in a small subset of the patients
during long-term follow-up periods. A review of 173 saliv-
ary gland MECs [19] noted that distant metastases affected16 patients (9.2%), most frequently in the lungs. The
analogous consequence was reported in some studies [20],
which indicated the prognosis of older patients is worse
and that hilar lymph node metastasis indicates worse prog-
nosis. In our experience, patients with low grade mucoepi-
dermoids can be expected to be cured following complete
resection. On the other hand, however, cases of high grade
malignant neoplasm surgery results in significantly worse
prognosis. The older patient in our series only survived for
15 months and died from the brain metastasis. It seems
that survival correlates with the presence of lymph node
metastasis. Nevertheless, the metastasis of low grade MEC
of the lung is rare and low grade MECs have a much better
prognosis than high grade carcinomas [21]. Patients with
low grade MECs generally have a good prognosis, with a
5-year survival rate of 95%, and adjuvant treatment is con-
sidered unnecessary. However, effective treatment mea-
sures for high grade tumors have not been established, and
these cases reportedly have a poor prognosis [22]. Under
such circumstances, there are several reports on the effi-
cacy of the tyrosine kinase inhibitor gefitinib in patients
with epidermal growth factor receptor (EGFR) gene muta-
tions [23,24], and this molecularly targeted therapy is likely
to improve the prognosis of cases with progressive high
grade and recurrent MEC.
Conclusions
MEC of the lung is a rare malignant neoplasm. A pre-
operative diagnosis of MEC of the lung is difficult for
the reason that the tumor can present as a solitary
pulmonary peripheral nodule or as a hilar mass from the
CT. Complete surgical resection is still the effective
treatment for pulmonary MEC. Patients with low grade
mucoepidermoids can be expected to be cured following
complete resection. However, in cases of high grade ma-
lignant neoplasm, surgery results in a significantly worse
prognosis. Careful histological typing plays a key role in
prediction of late results, and more studies and larger,
multicentric series are needed.
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